<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38299867</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>06</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2165-0497</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Mar</Month><Day>05</Day></PubDate></JournalIssue><Title>Microbiology spectrum</Title><ISOAbbreviation>Microbiol Spectr</ISOAbbreviation></Journal><ArticleTitle>Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT).</ArticleTitle><Pagination><StartPage>e0356323</StartPage><MedlinePgn>e0356323</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e03563-23</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/spectrum.03563-23</ELocationID><Abstract><AbstractText Label="UNLABELLED">This exploratory <i>post hoc</i> analysis assessed the incidence of respiratory viral coinfections and their impact on clinical outcomes in non-hospitalized adults with mild-to-moderate coronavirus disease-2019 (COVID-19) treated with molnupiravir versus placebo for 5 days in the Phase 2/3 MOVe-OUT trial (NCT04575597), which took place in October 2020 to January 2021 (Phase 2, <i>n</i> = 302) and May 2021 to October 2021 (Phase 3, <i>n</i> = 1,433). Among 1,735 total randomized participants, 1,674 had a baseline respiratory pathogen panel (NxTAG Respiratory Pathogen Panel for the Luminex MAGPIX instrument) performed and 69 (4.1%) were coinfected with at least one additional respiratory viral pathogen. Human rhinovirus/enterovirus (39/69, 56.5%) was the most common coinfection detected at baseline. In the modified intention-to-treat population, two participants with coinfecting respiratory RNA viruses were hospitalized and received respiratory interventions through Day 29, and none died; one participant in the molnupiravir group was coinfected with human rhinovirus/enterovirus, and one participant in the placebo group was coinfected with human metapneumovirus. Hospitalization or death occurred in 6.2% and 9.0% of non-coinfected participants in the molnupiravir versus placebo group, respectively, and over 90% did not require respiratory interventions. Most coinfecting respiratory RNA viruses detected at baseline were not detected at the end of therapy in both the molnupiravir and placebo groups. In summary, participants coinfected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and another respiratory RNA virus were not more likely to be hospitalized or die, or require respiratory interventions, compared to participants who were not coinfected with another respiratory RNA virus at baseline in both groups.</AbstractText><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Respiratory viral coinfections are known to occur with coronavirus disease-2019 (COVID-19). In a cohort of non-hospitalized adults with mild-to-moderate COVID-19 treated with molnupiravir versus placebo in the MOVe-OUT trial during October 2020 to October 2021, 4.1% of participants had a documented viral coinfection; human rhinovirus/enterovirus was the most common pathogen detected with the NxTAG Respiratory Pathogen Panel assay. Participants who had a coinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and another respiratory RNA virus were not more likely to have worse clinical outcomes compared to those participants without a viral coinfection, and many coinfecting respiratory RNA viruses were no longer detected at the end of the 5-day treatment period in both groups.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Matthew G</ForeName><Initials>MG</Initials><Identifier Source="ORCID">0000-0002-6023-1252</Identifier><AffiliationInfo><Affiliation>Merck &amp; Co., Inc., Rahway, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strizki</LastName><ForeName>Julie M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0009-0002-3893-9374</Identifier><AffiliationInfo><Affiliation>Merck &amp; Co., Inc., Rahway, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jensen</LastName><ForeName>Erin</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Merck &amp; Co., Inc., Rahway, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Jadestone Clinical Research, LLC, Rockville, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katlama</LastName><ForeName>Christine</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-5093-4800</Identifier><AffiliationInfo><Affiliation>AP-HP. Sorbonne Université, Hôpital-Pitié Salpêtrière, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Université Toulouse III Paul Sabatier, CHU de Toulouse, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fishchuk</LastName><ForeName>Roman</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>CNE Central City Clinical Hospital of Ivano-Frankivsk City Council, Ivano-Frankivsk, Ukraine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ponce-de-León</LastName><ForeName>Alfredo</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2640-2916</Identifier><AffiliationInfo><Affiliation>Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubiran, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fourie</LastName><ForeName>Nyda</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>IATROS International, Bloemfontein, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Chien-Yu</ForeName><Initials>C-Y</Initials><Identifier Source="ORCID">0000-0002-1886-0370</Identifier><AffiliationInfo><Affiliation>Taoyuan General Hospital, Taoyuan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCoy</LastName><ForeName>Dorothy</ForeName><Initials>D</Initials><Identifier Source="ORCID">0009-0008-9130-462X</Identifier><AffiliationInfo><Affiliation>Merck &amp; Co., Inc., Rahway, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vesnesky</LastName><ForeName>Mary</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Merck &amp; Co., Inc., Rahway, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Norice</LastName><ForeName>Carmelle T</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>Merck &amp; Co., Inc., Rahway, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Merck &amp; Co., Inc., Rahway, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams-Diaz</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Merck &amp; Co., Inc., Rahway, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Michelle L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Merck &amp; Co., Inc., Rahway, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carmelitano</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Merck &amp; Co., Inc., Rahway, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grobler</LastName><ForeName>Jay A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Merck &amp; Co., Inc., Rahway, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paschke</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Merck &amp; Co., Inc., Rahway, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Anda</LastName><ForeName>Carisa</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Merck &amp; Co., Inc., Rahway, New Jersey, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Merck (Merck &amp; Co.)</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Microbiol Spectr</MedlineTA><NlmUniqueID>101634614</NlmUniqueID><ISSNLinking>2165-0497</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>YA84KI1VEW</RegistryNumber><NameOfSubstance UI="C000656703">molnupiravir</NameOfSubstance></Chemical><Chemical><RegistryNumber>63231-63-0</RegistryNumber><NameOfSubstance UI="D012313">RNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>5CSZ8459RP</RegistryNumber><NameOfSubstance UI="D003562">Cytidine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006898">Hydroxylamines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060085" MajorTopicYN="Y">Coinfection</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003562" MajorTopicYN="N">Cytidine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006898" MajorTopicYN="Y">Hydroxylamines</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">molnupiravir</Keyword><Keyword MajorTopicYN="N">respiratory pathogens</Keyword></KeywordList><CoiStatement>Matthew G. Johnson, Julie M. Strizki, Erin Jensen, Dorothy McCoy, Mary Vesnesky, Carmelle T. Norice, Ying Zhang, Angela Williams-Diaz, Michelle L. Brown, Patricia Carmelitano, Jay A. Grobler, Amanda Paschke, and Carisa De Anda are employees of Merck Sharp &amp; Dohme LLC, a subsidiary of Merck &amp; Co., Inc. Jonathan Cohen: no conflicts of interest. Christine Katlama: no conflicts of interest. Roman Fishchuk: no conflicts of interest. Alfredo Ponce-de-León: Grants: NIH ATCC 1-4; Advisory boards: LATAM MSD, Gilead; Speaker: MSD, Gilead, Becton Dickinson, Qiagen. Nyda Fourie: no conflicts of interest. Chien-Yu Cheng: no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>1</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>1</Day><Hour>9</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38299867</ArticleId><ArticleId IdType="pmc">PMC10913477</ArticleId><ArticleId IdType="doi">10.1128/spectrum.03563-23</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Le Glass E, Hoang VT, Boschi C, Ninove L, Zandotti C, Boutin A, Bremond V, Dubourg G, Ranque S, Lagier JC, Million M, Fournier PE, Drancourt M, Gautret P, Colson P. 2021. Incidence and outcome of coinfections with SARS-CoV-2 and rhinovirus. Viruses 13:2528. doi:10.3390/v13122528</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13122528</ArticleId><ArticleId IdType="pmc">PMC8709236</ArticleId><ArticleId IdType="pubmed">34960797</ArticleId></ArticleIdList></Reference><Reference><Citation>Chekuri S, Szymczak WA, Goldstein DY, Nori P, Marrero Rolon R, Spund B, Singh-Tan S, Mohrmann L, Assa A, Southern WN, Baron SW. 2021. SARS-CoV-2 coinfection with additional respiratory virus does not predict severe disease: a retrospective cohort study. J Antimicrob Chemother 76:iii12–iii19. doi:10.1093/jac/dkab244</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkab244</ArticleId><ArticleId IdType="pmc">PMC8460099</ArticleId><ArticleId IdType="pubmed">34555160</ArticleId></ArticleIdList></Reference><Reference><Citation>Krumbein H, Kümmel LS, Fragkou PC, Thölken C, Hünerbein BL, Reiter R, Papathanasiou KA, Renz H, Skevaki C. 2023. Respiratory viral co-infections in patients with COVID-19 and associated outcomes: a systematic review and meta-analysis. Rev Med Virol 33:e2365. doi:10.1002/rmv.2365</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2365</ArticleId><ArticleId IdType="pmc">PMC9347814</ArticleId><ArticleId IdType="pubmed">35686619</ArticleId></ArticleIdList></Reference><Reference><Citation>Boschi C, Hoang VT, Giraud-Gatineau A, Ninove L, Lagier J-C, La Scola B, Gautret P, Raoult D, Colson P. 2021. Coinfections with SARS-CoV-2 and other respiratory viruses in Southeastern France: a matter of sampling time. J Med Virol 93:1878–1881. doi:10.1002/jmv.26692</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26692</ArticleId><ArticleId IdType="pmc">PMC7753800</ArticleId><ArticleId IdType="pubmed">33230812</ArticleId></ArticleIdList></Reference><Reference><Citation>Hazra D, Chandy GM, Thanjavurkar A, Gunasekaran K, Nekkanti AC, Pal R, Moorthy M, Abhilash KPP. 2023. A clinico-epidemiological profile, coinfections and outcome of patients with influenza like illnesses (ILI) presenting to the emergency department during the COVID-19 pandemic. J Family Med Prim Care 12:672–678. doi:10.4103/jfmpc.jfmpc_1705_22</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/jfmpc.jfmpc_1705_22</ArticleId><ArticleId IdType="pmc">PMC10259566</ArticleId><ArticleId IdType="pubmed">37312766</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah MM, Patel K, Milucky J, Taylor CA, Reingold A, Armistead I, Meek J, Anderson EJ, Weigel A, Reeg L, Como-Sabetti K, Ropp SL, Muse A, Bushey S, Shiltz E, Sutton M, Talbot HK, Chatelain R, Havers FP, Team CC-NS . 2023. Bacterial and viral infections among adults hospitalized with COVID-19, COVID-NET, 14 States. Influenza Other Respir Viruses 17:e13107. doi:10.1111/irv.13107</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.13107</ArticleId><ArticleId IdType="pmc">PMC9981874</ArticleId><ArticleId IdType="pubmed">36875205</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Sulaiman K, Aljuhani O, Badreldin HA, Korayem GB, Alenazi AA, Alharbi AH, Alghamdi A, Alhubaishi A, Altebainawi AF, Bosaeed M, Alotaibi R, Alawad A, Alnajjar N, Saleh KB, Sait WA, Alsohimi S, Alanizy MM, Almuqbil SA, Al Sulaihim I, Vishwakarma R, Alalawi M, Alhassan F, Alghnam S. 2023. The clinical outcomes of COVID-19 critically ill patients co-infected with other respiratory viruses: a multicenter, cohort study. BMC Infect Dis 23:103. doi:10.1186/s12879-023-08072-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-023-08072-8</ArticleId><ArticleId IdType="pmc">PMC9944396</ArticleId><ArticleId IdType="pubmed">36814218</ArticleId></ArticleIdList></Reference><Reference><Citation>Swets MC, Russell CD, Harrison EM, Docherty AB, Lone N, Girvan M, Hardwick HE, Visser LG, Openshaw PJM, Groeneveld GH, Semple MG, Baillie JK. 2022. SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses. Lancet 399:1463–1464. doi:10.1016/S0140-6736(22)00383-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00383-X</ArticleId><ArticleId IdType="pmc">PMC8956294</ArticleId><ArticleId IdType="pubmed">35344735</ArticleId></ArticleIdList></Reference><Reference><Citation>Trifonova I, Christova I, Madzharova I, Angelova S, Voleva S, Yordanova R, Tcherveniakova T, Krumova S, Korsun N. 2022. Clinical significance and role of coinfections with respiratory pathogens among individuals with confirmed severe acute respiratory syndrome coronavirus-2 infection. Front Public Health 10:959319. doi:10.3389/fpubh.2022.959319</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2022.959319</ArticleId><ArticleId IdType="pmc">PMC9479447</ArticleId><ArticleId IdType="pubmed">36117597</ArticleId></ArticleIdList></Reference><Reference><Citation>Aghbash PS, Eslami N, Shirvaliloo M, Baghi HB. 2021. Viral coinfections in COVID-19. J Med Virol 93:5310–5322. doi:10.1002/jmv.27102</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27102</ArticleId><ArticleId IdType="pmc">PMC8242380</ArticleId><ArticleId IdType="pubmed">34032294</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar N, Sharma S, Barua S, Tripathi BN, Rouse BT. 2018. Virological and immunological outcomes of coinfections. Clin Microbiol Rev 31:e00111-17. doi:10.1128/CMR.00111-17</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00111-17</ArticleId><ArticleId IdType="pmc">PMC6148187</ArticleId><ArticleId IdType="pubmed">29976554</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahl A, Gralinski LE, Johnson CE, Yao W, Kovarova M, Dinnon KH, Liu H, Madden VJ, Krzystek HM, De C, et al. . 2021. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature 591:451–457. doi:10.1038/s41586-021-03312-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03312-w</ArticleId><ArticleId IdType="pmc">PMC7979515</ArticleId><ArticleId IdType="pubmed">33561864</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelnabi R, Foo CS, De Jonghe S, Maes P, Weynand B, Neyts J. 2021. Molnupiravir inhibits the replication of the emerging SARS-CoV-2 variants of concern (VoCs) in a hamster infection model. J Infect Dis 224:749–753. doi:10.1093/infdis/jiab361</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab361</ArticleId><ArticleId IdType="pmc">PMC8408768</ArticleId><ArticleId IdType="pubmed">34244768</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheahan TP, Sims AC, Zhou S, Graham RL, Pruijssers AJ, Agostini ML, Leist SR, Schäfer A, Dinnon KH, Stevens LJ, et al. . 2020. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med 12:eabb5883. doi:10.1126/scitranslmed.abb5883</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abb5883</ArticleId><ArticleId IdType="pmc">PMC7164393</ArticleId><ArticleId IdType="pubmed">32253226</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon JJ, Toots M, Lee S, Lee ME, Ludeke B, Luczo JM, Ganti K, Cox RM, Sticher ZM, Edpuganti V, Mitchell DG, Lockwood MA, Kolykhalov AA, Greninger AL, Moore ML, Painter GR, Lowen AC, Tompkins SM, Fearns R, Natchus MG, Plemper RK. 2018. Orally efficacious broad-spectrum ribonucleoside analog inhibitor of influenza and respiratory syncytial viruses. Antimicrob Agents Chemother 62:e00766-18. doi:10.1128/AAC.00766-18</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00766-18</ArticleId><ArticleId IdType="pmc">PMC6105843</ArticleId><ArticleId IdType="pubmed">29891600</ArticleId></ArticleIdList></Reference><Reference><Citation>Urakova N, Kuznetsova V, Crossman DK, Sokratian A, Guthrie DB, Kolykhalov AA, Lockwood MA, Natchus MG, Crowley MR, Painter GR, Frolova EI, Frolov I. 2018. β-d-N4-hydroxycytidine is a potent anti-alphavirus compound that induces a high level of mutations in the viral genome. J Virol 92:e01965-17. doi:10.1128/JVI.01965-17</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01965-17</ArticleId><ArticleId IdType="pmc">PMC5774879</ArticleId><ArticleId IdType="pubmed">29167335</ArticleId></ArticleIdList></Reference><Reference><Citation>Strizki JM, Gaspar JM, Howe JA, Hutchins B, Mohri H, Nair MS, Kinek KC, McKenna P, Goh SL, Murgolo N, Martinez MA. 2023. Molnupiravir maintains anti-viral activity against SARS-CoV-2 variants and exhibits a high barrier to the development of resistance. Antimicrob Agents Chemother:e0095323. doi:10.1128/aac.00953-23</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/aac.00953-23</ArticleId><ArticleId IdType="pmc">PMC10777856</ArticleId><ArticleId IdType="pubmed">38047645</ArticleId></ArticleIdList></Reference><Reference><Citation>Caraco Y, Crofoot GE, Moncada PA, Galustyan AN, Musungaie DB, Payne B, Kovalchuk E, Gonzalez A, Brown ML, Williams-Diaz A, Gao W, Strizki JM, Grobler J, Du J, Assaid CA, Paschke A, Butterton JR, Johnson MG, De Anda C. 2022. Phase 2/3 trial of molnupiravir for treatment of COVID-19 in nonhospitalized adults. NEJM Evidence 1. doi:10.1056/EVIDoa2100043</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/EVIDoa2100043</ArticleId><ArticleId IdType="pubmed">38319179</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, Martín-Quirós A, Caraco Y, Williams-Diaz A, Brown ML, Du J, Pedley A, Assaid C, Strizki J, Grobler JA, Shamsuddin HH, Tipping R, Wan H, Paschke A, Butterton JR, Johnson MG, De Anda C, Group M-OS . 2022. Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients. N Engl J Med 386:509–520. doi:10.1056/NEJMoa2116044</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116044</ArticleId><ArticleId IdType="pmc">PMC8693688</ArticleId><ArticleId IdType="pubmed">34914868</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson MG, Puenpatom A, Moncada PA, Burgess L, Duke ER, Ohmagari N, Wolf T, Bassetti M, Bhagani S, Ghosn J, Zhang Y, Wan H, Williams-Diaz A, Brown ML, Paschke A, De Anda C. 2022. Effect of molnupiravir on biomarkers, respiratory interventions, and medical services in COVID-19: a randomized, placebo-controlled trial. Ann Intern Med 175:1126–1134. doi:10.7326/M22-0729</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M22-0729</ArticleId><ArticleId IdType="pmc">PMC9186515</ArticleId><ArticleId IdType="pubmed">35667065</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott SJ, Pfotenhauer B, Weiner JJ, Hilleshiem J, Khubbar M, Bhattacharyya S. 2021. Respiratory pathogen coinfections in SARS-CoV-2-positive patients in Southeastern Wisconsin: a retrospective analysis. Microbiol Spectr 9:e0083121. doi:10.1128/Spectrum.00831-21</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/Spectrum.00831-21</ArticleId><ArticleId IdType="pmc">PMC8528126</ArticleId><ArticleId IdType="pubmed">34668725</ArticleId></ArticleIdList></Reference><Reference><Citation>Smedberg JR, DiBiase LM, Hawken SE, Allen A, Mohan S, Santos C, Smedberg T, Barzin AH, Wohl DA, Miller MB. 2022. Reduction and persistence of co-circulating respiratory viruses during the SARS-CoV-2 pandemic. Am J Infect Control 50:1064–1066. doi:10.1016/j.ajic.2022.06.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajic.2022.06.008</ArticleId><ArticleId IdType="pmc">PMC9188982</ArticleId><ArticleId IdType="pubmed">35709970</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu D, Lu J, Cao L, Ma X, Liu Q, Liu Y, Zhang Z. 2020. Positive effects of COVID-19 control measures on pneumonia prevention. Int J Infect Dis 96:548–549. doi:10.1016/j.ijid.2020.05.069</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.05.069</ArticleId><ArticleId IdType="pmc">PMC7250071</ArticleId><ArticleId IdType="pubmed">32470599</ArticleId></ArticleIdList></Reference><Reference><Citation>Donelan SV, Spitzer S, Spitzer E. 2019. Inability to locally differentiate rhinovirus/enterovirus results impacts infection control practices. Open Forum Infect Dis 6:S989–S990. doi:10.1093/ofid/ofz360.2476</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofz360.2476</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs SE, Lamson DM, St George K, Walsh TJ. 2013. Human rhinoviruses. Clin Microbiol Rev 26:135–162. doi:10.1128/CMR.00077-12</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00077-12</ArticleId><ArticleId IdType="pmc">PMC3553670</ArticleId><ArticleId IdType="pubmed">23297263</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinky L, Dobrovolny HM. 2016. Coinfections of the respiratory tract: viral competition for resources. PLoS One 11:e0155589. doi:10.1371/journal.pone.0155589</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0155589</ArticleId><ArticleId IdType="pmc">PMC4873262</ArticleId><ArticleId IdType="pubmed">27196110</ArticleId></ArticleIdList></Reference><Reference><Citation>Dee K, Goldfarb DM, Haney J, Amat JAR, Herder V, Stewart M, Szemiel AM, Baguelin M, Murcia PR. 2021. Human rhinovirus infection blocks severe acute respiratory syndrome coronavirus 2 replication within the respiratory epithelium: implications for COVID-19 epidemiology. J Infect Dis 224:31–38. doi:10.1093/infdis/jiab147</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab147</ArticleId><ArticleId IdType="pmc">PMC8083659</ArticleId><ArticleId IdType="pubmed">33754149</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheemarla NR, Watkins TA, Mihaylova VT, Wang B, Zhao D, Wang G, Landry ML, Foxman EF. 2021. Dynamic innate immune response determines susceptibility to SARS-CoV-2 infection and early replication kinetics. J Exp Med 218:e20210583. doi:10.1084/jem.20210583</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20210583</ArticleId><ArticleId IdType="pmc">PMC8210587</ArticleId><ArticleId IdType="pubmed">34128960</ArticleId></ArticleIdList></Reference><Reference><Citation>Greer RM, McErlean P, Arden KE, Faux CE, Nitsche A, Lambert SB, Nissen MD, Sloots TP, Mackay IM. 2009. Do rhinoviruses reduce the probability of viral co-detection during acute respiratory tract infections. J Clin Virol 45:10–15. doi:10.1016/j.jcv.2009.03.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2009.03.008</ArticleId><ArticleId IdType="pmc">PMC7185458</ArticleId><ArticleId IdType="pubmed">19376742</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinky L, DeAguero JR, Remien CH, Smith AM. 2023. How interactions during viral-viral coinfection can shape infection kinetics. Viruses 15:1303. doi:10.3390/v15061303</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15061303</ArticleId><ArticleId IdType="pmc">PMC10301061</ArticleId><ArticleId IdType="pubmed">37376603</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozlovskaya LI, Golinets AD, Eletskaya AA, Orlov AA, Palyulin VA, Kochetkov SN, Alexandrova LA, Osolodkin DI. 2018. Selective inhibition of enterovirus A species members' reproduction by furano[2, 3-D]pyrimidine nucleosides revealed by antiviral activity profiling against (+)ssRNA viruses. ChemistrySelect 3:2321–2325. doi:10.1002/slct.201703052</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/slct.201703052</ArticleId><ArticleId IdType="pmc">PMC7169607</ArticleId><ArticleId IdType="pubmed">32328513</ArticleId></ArticleIdList></Reference><Reference><Citation>Toots M, Yoon JJ, Cox RM, Hart M, Sticher ZM, Makhsous N, Plesker R, Barrena AH, Reddy PG, Mitchell DG, Shean RC, Bluemling GR, Kolykhalov AA, Greninger AL, Natchus MG, Painter GR, Plemper RK. 2019. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci Transl Med 11:eaax5866. doi:10.1126/scitranslmed.aax5866</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aax5866</ArticleId><ArticleId IdType="pmc">PMC6848974</ArticleId><ArticleId IdType="pubmed">31645453</ArticleId></ArticleIdList></Reference><Reference><Citation>Toots M, Yoon JJ, Hart M, Natchus MG, Painter GR, Plemper RK. 2020. Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model. Transl Res 218:16–28. doi:10.1016/j.trsl.2019.12.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2019.12.002</ArticleId><ArticleId IdType="pmc">PMC7568909</ArticleId><ArticleId IdType="pubmed">31945316</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Li P, Solanki K, Li Y, Ma Z, Peppelenbosch MP, Baig MS, Pan Q. 2021. Viral polymerase binding and broad-spectrum antiviral activity of molnupiravir against human seasonal coronaviruses. Virology 564:33–38. doi:10.1016/j.virol.2021.09.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2021.09.009</ArticleId><ArticleId IdType="pmc">PMC8486977</ArticleId><ArticleId IdType="pubmed">34619630</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Liu M, Yan Y, Wang Z, Dai Q, Yang X, Guo X, Li W, Chen X, Cao R, Zhong W. 2022. Molnupiravir and its active form, EIDD-1931, show potent antiviral activity against enterovirus infections in vitro and in vivo. Viruses 14:1142. doi:10.3390/v14061142</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14061142</ArticleId><ArticleId IdType="pmc">PMC9227765</ArticleId><ArticleId IdType="pubmed">35746614</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan Z, Chen C, Li Y, Yan D, Zhang X, Jiang D, Yang S, Li L. 2021. Impact of coinfection with SARS-CoV-2 and influenza on disease severity: a systematic review and meta-analysis. Front Public Health 9:773130. doi:10.3389/fpubh.2021.773130</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2021.773130</ArticleId><ArticleId IdType="pmc">PMC8703010</ArticleId><ArticleId IdType="pubmed">34957025</ArticleId></ArticleIdList></Reference><Reference><Citation>Pawlowski C, Silvert E, O’Horo JC, Lenehan PJ, Challener D, Gnass E, Murugadoss K, Ross J, Speicher L, Geyer H, Venkatakrishnan AJ, Badley AD, Soundararajan V. 2022. SARS-CoV-2 and influenza coinfection throughout the COVID-19 pandemic: an assessment of coinfection rates, cohort characteristics, and clinical outcomes. PNAS Nexus 1:pgac071. doi:10.1093/pnasnexus/pgac071</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/pnasnexus/pgac071</ArticleId><ArticleId IdType="pmc">PMC9291226</ArticleId><ArticleId IdType="pubmed">35860600</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>